228 related articles for article (PubMed ID: 12959324)
1. Three-drug combinations of emivirine and nucleoside reverse transcriptase inhibitors in vitro: long-term culture of HIV-1-infected cells and breakthrough viruses.
Nitanda T; Wang X; Somekawa K; Yuasa S; Baba M
Antivir Chem Chemother; 2001 May; 12(3):161-7. PubMed ID: 12959324
[TBL] [Abstract][Full Text] [Related]
2. In vitro analysis of synergism and antagonism of different nucleoside/nucleotide analogue combinations on the inhibition of human immunodeficiency virus type 1 replication.
Perez-Olmeda M; Garcia-Perez J; Mateos E; Spijkers S; Ayerbe MC; Carcas A; Alcami J
J Med Virol; 2009 Feb; 81(2):211-6. PubMed ID: 19107982
[TBL] [Abstract][Full Text] [Related]
3. Long-term exposure of HIV type 1-infected cell cultures to combinations of the novel quinoxaline GW420867X with lamivudine, abacavir, and a variety of nonnucleoside reverse transcriptase inhibitors.
Balzarini J; De Clercq E; Carbonez A; Burt V; Kleim JP
AIDS Res Hum Retroviruses; 2000 Apr; 16(6):517-28. PubMed ID: 10777142
[TBL] [Abstract][Full Text] [Related]
4. Nucleoside analogue mutations and Q151M in HIV-1 subtype A/E infection treated with nucleoside reverse transcriptase inhibitors.
Sirivichayakul S; Ruxrungtham K; Ungsedhapand C; Techasathit W; Ubolyam S; Chuenyam T; Emery S; Cooper D; Lange J; Phanuphak P
AIDS; 2003 Sep; 17(13):1889-96. PubMed ID: 12960821
[TBL] [Abstract][Full Text] [Related]
5. Drug resistance and drug combination features of the human immunodeficiency virus inhibitor, BCH-10652 [(+/-)-2'-deoxy-3'-oxa-4'-thiocytidine, dOTC].
Taylor DL; Ahmed PS; Tyms AS; Wood LJ; Kelly LA; Chambers P; Clarke J; Bedard J; Bowlin TL; Rando RF
Antivir Chem Chemother; 2000 Jul; 11(4):291-301. PubMed ID: 10950391
[TBL] [Abstract][Full Text] [Related]
6. Vitamin D attenuates nucleoside reverse transcriptase inhibitor induced human skeletal muscle mitochondria DNA depletion.
Campbell GR; Pallack ZT; Spector SA
AIDS; 2013 Jun; 27(9):1397-401. PubMed ID: 23435299
[TBL] [Abstract][Full Text] [Related]
7. Correlation between intracellular pharmacological activation of nucleoside analogues and HIV suppression in vitro.
Hoggard PG; Sales SD; Kewn S; Sunderland D; Khoo SH; Hart CA; Back DJ
Antivir Chem Chemother; 2000 Nov; 11(6):353-8. PubMed ID: 11227992
[TBL] [Abstract][Full Text] [Related]
8. Pharmacodynamic studies (PD) of didanosine (ddI) alone and in combination with azidothymidine (AZT) in human T-cells; a stochastic biochemical approach to antiretroviral nucleoside drug combination in inhibiting HIV-reverse transcriptase (RT).
Periclou AP; Nandy P; Avramis VI
In Vivo; 2000; 14(3):377-88. PubMed ID: 10904870
[TBL] [Abstract][Full Text] [Related]
9. Mutations conferring resistance to zidovudine diminish the antiviral effect of stavudine plus didanosine.
Izopet J; Bicart-See A; Pasquier C; Sandres K; Bonnet E; Marchou B; Puel J; Massip P
J Med Virol; 1999 Dec; 59(4):507-11. PubMed ID: 10534734
[TBL] [Abstract][Full Text] [Related]
10. Combination therapy for patients with HIV-1 infection: the use of dual nucleoside analogues with protease inhibitors and other agents.
Gulick R
AIDS; 1998; 12 Suppl 3():S17-22. PubMed ID: 15168719
[TBL] [Abstract][Full Text] [Related]
11. Relative mutagenic potencies of several nucleoside analogs, alone or in drug pairs, at the HPRT and TK loci of human TK6 lymphoblastoid cells.
Carter MM; Torres SM; Cook DL; McCash CL; Yu M; Walker VE; Walker DM
Environ Mol Mutagen; 2007; 48(3-4):239-47. PubMed ID: 17358029
[TBL] [Abstract][Full Text] [Related]
12. Combined analysis of two-year follow-up from two open-label randomized trials comparing efficacy of three nucleoside reverse transcriptase inhibitor backbones for previously untreated HIV-1 infection: OzCombo 1 and 2.
Amin J; Moore A; Carr A; French MA; Law M; Emery S; Cooper DA;
HIV Clin Trials; 2003; 4(4):252-61. PubMed ID: 12916011
[TBL] [Abstract][Full Text] [Related]
13. Three-drug combination of MKC-442, lamivudine and zidovudine in vitro: potential approach towards effective chemotherapy against HIV-1.
Piras G; Nakade K; Yuasa S; Baba M
AIDS; 1997 Mar; 11(4):469-75. PubMed ID: 9084794
[TBL] [Abstract][Full Text] [Related]
14. Comparison of antiviral activity of regimens containing nucleos(t)ide (NUC) Pairs in HIV-Infected Patients Initiating REScue therapy (The NUCREST Study).
Pérez-Molina JA; Serrano O; Milinkovic A; Domingo P; Currán A; Knobel H; Gaspar G; Rodrigo A; Jiménez-Expósito MJ; Hernández-Novoa B; Moreno S; The NUCREST Study
HIV Clin Trials; 2010; 11(5):294-302. PubMed ID: 21126959
[TBL] [Abstract][Full Text] [Related]
15. Concomitant combination therapy for HIV infection preferable over sequential therapy with 3TC and non-nucleoside reverse transcriptase inhibitors.
Balzarini J; Pelemans H; Karlsson A; De ClercQ E; Kleim JP
Proc Natl Acad Sci U S A; 1996 Nov; 93(23):13152-7. PubMed ID: 8917560
[TBL] [Abstract][Full Text] [Related]
16. Susceptibility of human T cell leukemia virus type 1 to reverse-transcriptase inhibitors: evidence for resistance to lamivudine.
García-Lerma JG; Nidtha S; Heneine W
J Infect Dis; 2001 Aug; 184(4):507-10. PubMed ID: 11471110
[TBL] [Abstract][Full Text] [Related]
17. Nucleoside combinations for antiretroviral therapy: efficacy of stavudine in combination with either didanosine or lamivudine.
Fisher M
AIDS; 1998; 12 Suppl 3():S9-16. PubMed ID: 15168718
[TBL] [Abstract][Full Text] [Related]
18. Metabolism of 2',3'-dideoxy-2',3'-didehydro-beta-L(-)-5-fluorocytidine and its activity in combination with clinically approved anti-human immunodeficiency virus beta-D(+) nucleoside analogs in vitro.
Dutschman GE; Bridges EG; Liu SH; Gullen E; Guo X; Kukhanova M; Cheng YC
Antimicrob Agents Chemother; 1998 Jul; 42(7):1799-804. PubMed ID: 9661024
[TBL] [Abstract][Full Text] [Related]
19. Susceptibility of Human Endogenous Retrovirus Type K to Reverse Transcriptase Inhibitors.
Contreras-Galindo R; Dube D; Fujinaga K; Kaplan MH; Markovitz DM
J Virol; 2017 Dec; 91(23):. PubMed ID: 28931682
[TBL] [Abstract][Full Text] [Related]
20. Differential susceptibility of retroviruses to nucleoside analogues.
Rosenblum LL; Patton G; Grigg AR; Frater AJ; Cain D; Erlwein O; Hill CL; Clarke JR; McClure MO
Antivir Chem Chemother; 2001 Mar; 12(2):91-7. PubMed ID: 11527046
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
